| Renal function in patients with non-dialysis chronic kidney disease receivingintravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial. | BMC Nephrol | 2017 Jan 17 | 28095881 |
| East and West African milk products are reservoirs for human and livestock-associated Staphylococcus aureus. | Food Microbiol | 2017 Aug | 28400021 |
| Clinical efficacy of ferric carboxymaltose treatment in patients with restlesslegs syndrome. | Sleep Med | 2016 Sep | 27823710 |
| Effect of antibiotics on cellular stress generated in Shiga toxin-producing Escherichia coli O157:H7 and non-O157 biofilms. | Toxicol In Vitro | 2015 Oct | 26130220 |
| Optimizing iron delivery in the management of anemia: patient considerations and the role of ferric carboxymaltose. | Drug Des Devel Ther | 2014 Dec 11 | 25525337 |
| Comparative review of the safety and efficacy of ferric carboxymaltose versusstandard medical care for the treatment of iron deficiency anemia in bariatricand gastric surgery patients. | Obes Surg | 2013 Sep | 23553506 |
| Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatorybowel disease. | Clin Gastroenterol Hepatol | 2013 Mar | 23078888 |
| Hepcidin levels predict nonresponsiveness to oral iron therapy in patients withiron deficiency anemia. | Am J Hematol | 2013 Feb | 23335357 |
| Penetration of fosfomycin into IPEC-J2 cells in the presence or absence of deoxynivalenol. | PLoS One | 2013 | 24040387 |
| Serotype, Shiga toxin (Stx) type, and antimicrobial resistance of Stx-producing Escherichia coli isolated from humans in Shizuoka Prefecture, Japan (2003-2007). | Jpn J Infect Dis | 2012 | 22627299 |